Literature DB >> 17562929

Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.

Pascale Ribaï1, Karine Nguyen, Valérie Hahn-Barma, Isabelle Gourfinkel-An, Marie Vidailhet, Antoine Legout, Catherine Dodé, Alexis Brice, Alexandra Dürr.   

Abstract

BACKGROUND: Juvenile Huntington disease (JHD) is a rare clinical entity characterized by an age at onset younger than 20 years. Patients usually have an expansion of more than 60 CAG repeats in the Huntington disease (HD) gene, and the disease is usually inherited from the father. In general, precise age at onset is difficult to assess in HD because of insidious onset and anosognosia. Onset of motor difficulty signs is usually used to define age at onset.
OBJECTIVES: To evaluate diagnosis delay in patients with JHD and to analyze the clinical and genetic features of JHD.
DESIGN: Retrospective clinical and genetic review.
SETTING: Referral center for HD at Salpêtrière Hospital, Paris, France. PATIENTS: Twenty-nine patients with HD with onset before or at age 20 years who carried an abnormal CAG repeat expansion in the HD gene.
RESULTS: The mean +/- SD delay before diagnosis was 9 +/- 6 years (range, 0-21 years). The most remarkable signs at onset were severe psychiatric and cognitive disturbances (19 of 29 [65.5%]); rigidity was absent. Unusual signs at onset included myoclonic head tremor in 3 patients, severe isolated drug or alcohol addiction in 2, psychotic disorder in 1, and difficulty writing in 1. One patient had progressive cerebellar signs associated with cerebellar atrophy on cerebral magnetic resonance imaging before signs suggestive of HD appeared. During the course of the disease, psychiatric disturbances were severe, with at least 1 suicide attempt in 7 of 29 patients. Transmission was maternal in 25% of patients. Forty-six percent of patients with JHD had fewer than 60 CAG repeats; 6 of these patients inherited the disease from their father. Anticipation (mean +/- SD, 18 +/- 9 vs 25 +/- 11 years; P = .27) and age at onset (mean +/- SD, 17.14 +/- 2.2 vs 13.29 +/- 5.5 years; P = .09) was similar in patients with maternal compared with paternal transmission, respectively.
CONCLUSIONS: Patients with JHD started showing disease symptoms through nonspecific features, mostly psychiatric and cognitive difficulties. This led to misdiagnosis or diagnosis delay, especially in cases without a familial history of HD. Maternal transmissions and expansions of fewer than 60 CAG repeats were unexpectedly frequent in this series and should not be considered exceptional.

Entities:  

Mesh:

Year:  2007        PMID: 17562929     DOI: 10.1001/archneur.64.6.813

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  36 in total

1.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

Review 2.  Therapy in Huntington's disease: where are we?

Authors:  Martha A Nance
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 3.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

4.  [Huntington's chorea mimicking adult attention deficit hyperactivity disorder].

Authors:  M Kraemer; S Haertig; A Hill; J Uekermann; J Wiltfang; B Kis
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

Review 5.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 6.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

7.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

8.  The personal experience of parenting a child with juvenile Huntington's disease: perceptions across Europe.

Authors:  Virginia Eatough; Helen Santini; Christine Eiser; Marie-Louise Goller; Wioletta Krysa; 'Annunziata' de Nicola; Matteo Paduanello; Martina Petrollini; Maria Rakowicz; Ferdinando Squitieri; Aad Tibben; Katie Lee Weille; Bernhard Landwehrmeyer; Oliver Quarrell; Jonathan A Smith
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

9.  Recent advances in the management of choreas.

Authors:  Jean-Marc Burgunder
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

Review 10.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.